A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Eligible age
18+ yrs
Accepts
All genders
Locations
23 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Sponsor: BeOne Medicines
You may qualify if…
- ✓ Confirmed diagnosis of CLL/SLL that meets the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
- ✓ Received one or more prior therapies for CLL/SLL. For each line of therapy, participants must have received at least 2 cycles of the therapy
- ✓ Participants with prior BCL2i exposure are eligible if remission duration was ≥3 years with ≥2 years from last BCL2i intake
- ✓ Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2
- ✓ Adequate organ function
You may not qualify if…
- ✕ Known active prolymphocytic leukemia or currently suspected Richter's transformation
- ✕ Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug
- ✕ Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent
- ✕ Known central nervous system involvement by CLL/SLL
- ✕ Severe or debilitating pulmonary disease
- ✕ Clinically significant cardiovascular disease
- ✕ NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Where it's recruiting
Laguna Hills · Orange · Palo Alto · San Diego
Aurora
New Haven · Norwich
Weston
Chicago · Niles
Iowa City · Waukee
Louisville
Baton Rouge
Baltimore
Boston
Grand Rapids
Rochester
Source: ClinicalTrials.gov · NCT06943872 · last updated 2026-08-24